1-9 of 9
ruxolitinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN

Aaron T. Gerds
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 407–414.
https://doi.org/10.1182/hematology.2019000048
Published: 2019
Journal Articles

Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF

Robyn M. Scherber, Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 118–126.
https://doi.org/10.1182/asheducation-2018.1.118
Published: 2018
Journal Articles

What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Alessandro M. Vannucchi, Paola Guglielmelli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 480–488.
https://doi.org/10.1182/asheducation-2017.1.480
Published: 2017
Journal Articles

Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond

Claire N. Harrison, Donal P. McLornan
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 489–497.
https://doi.org/10.1182/asheducation-2017.1.489
Published: 2017
Journal Articles

Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis

John Mascarenhas
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 329–339.
https://doi.org/10.1182/asheducation-2015.1.329
Published: 2015
Journal Articles

Therapy for myeloproliferative neoplasms: when, which agent, and how?

Holly L. Geyer, Ruben A. Mesa
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 277–286.
https://doi.org/10.1182/asheducation-2014.1.277
Published: 2014
Journal Articles

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Edwin Chen, Ann Mullally
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 268–276.
https://doi.org/10.1182/asheducation-2014.1.268
Published: 2014
Journal Articles

JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside

Jason Gotlib
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 529–537.
https://doi.org/10.1182/asheducation-2013.1.529
Published: 2013
Journal Articles

Therapeutic potential of JAK2 inhibitors

Srdan Verstovsek
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 636–642.
https://doi.org/10.1182/asheducation-2009.1.636
Published: 2009